Cargando…

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids

In this nonsystematic review and opinion, including articles primarily selected from PubMed, we examine the pharmacological and nonpharmacological treatments of neonatal abstinence syndrome (NAS) in order to craft a reasonable opinion to help forge a paradigm shift in the treatment and prevention of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceccanti, Mauro, Blum, Kenneth, Bowirrat, Abdalla, Dennen, Catherine A., Braverman, Eric R., Baron, David, Mclaughlin, Thomas, Giordano, John, Gupta, Ashim, Downs, Bernard W., Bagchi, Debasis, Barh, Debmalya, Elman, Igor, Thanos, Panayotis K., Badgaiyan, Rajendra D., Edwards, Drew, Gold, Mark S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782293/ https://www.ncbi.nlm.nih.gov/pubmed/36556236 http://dx.doi.org/10.3390/jpm12122015

Ejemplares similares

Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?
por: Blum, Kenneth, et al.
Publicado: (2023)

How to Combat the Global Opioid Crisis
por: Dennen A., Catherine, et al.
Publicado: (2023)

Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy: Fighting Iatrogenic Opioid Dependence
por: Blum, Kenneth, et al.
Publicado: (2013)

Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing
por: Modestino, Edward Justin, et al.
Publicado: (2022)

Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy—A Case-Series
por: Bajaj, Anish, et al.
Publicado: (2023)

Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case–Control Subjects
por: Blum, Kenneth, et al.
Publicado: (2022)

Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
por: Blum, Kenneth, et al.
Publicado: (2022)

Genetic Addiction Risk and Psychological Profiling Analyses for “Preaddiction” Severity Index
por: Blum, Kenneth, et al.
Publicado: (2022)

A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
por: Blum, Kenneth, et al.
Publicado: (2021)

Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”
por: Blum, Kenneth, et al.
Publicado: (2022)

Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia’s Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family
por: Dennen, Catherine A., et al.
Publicado: (2022)

Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors
por: Gupta, Ashim, et al.
Publicado: (2022)

Neurogenetics and Epigenetics of Loneliness
por: Bowirrat, Abdalla, et al.
Publicado: (2023)

High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial
por: Moran, Mark, et al.
Publicado: (2021)

Neurogenetic and Epigenetic Aspects of Cannabinoids
por: Dennen, Catherine A., et al.
Publicado: (2022)

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)
por: Blum, K, et al.
Publicado: (2019)

DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave(®) and Other Neurobiologically Based Modalities to Address Complexities of Chronic Pain in a Female Diagnosed with Reward Deficiency Syndrome (RDS): Emergence of Induction of “Dopamine Homeostasis” in the Face of the Opioid Crisis
por: Bajaj, Anish, et al.
Publicado: (2022)

Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
por: Blum, Kenneth, et al.
Publicado: (2023)

KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?
por: McLaughlin, Thomas, et al.
Publicado: (2016)

Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
por: Blum, Kenneth, et al.
Publicado: (2021)

Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions
por: Blum, Kenneth, et al.
Publicado: (2021)

Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2014)

“Preaddiction” construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation
por: Blum, Kenneth, et al.
Publicado: (2022)

Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?
por: Madigan, Margaret A., et al.
Publicado: (2022)

Metheamphetamine for Children: Are We Over or Under Dosing?
por: Blum, Kenneth, et al.
Publicado: (2023)

Hypothesizing that a Pro-Dopaminergic Regulator (KB220z(™) Liquid Variant) can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence
por: Blum, Kenneth, et al.
Publicado: (2016)

Offering a putative neurobiological “dopamine homeostatic” solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of “precision behavioral management”
por: Blum, Kenneth, et al.
Publicado: (2022)

Angiotensin-converting enzyme and enkephalinase in human breast cyst fluid.
por: Frame, K. L., et al.
Publicado: (1996)

Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”?
por: Blum, Kenneth, et al.
Publicado: (2022)

Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors
por: Blum, Kenneth, et al.
Publicado: (2018)

“Pro-dopamine regulation (KB220Z™)” as a long-term therapeutic modality to overcome reduced resting state dopamine tone in opiate/opioid epidemic in America
por: Blum, K, et al.
Publicado: (2016)

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018)

Hypothesizing that, A Pro-Dopamine Regulator (KB220Z) Should Optimize, but Not Hyper-Activate the Activity of Trace Amine-Associated Receptor 1 (TAAR-1) and Induce Anti-Craving of Psychostimulants in the Long-Term
por: Blum, Kenneth, et al.
Publicado: (2016)

Anti-Inflammatory Effect of Homo- and Heterodimers of Natural Enkephalinase Inhibitors in Experimental Colitis in Mice
por: Sobocińska, Małgorzata, et al.
Publicado: (2020)

Enhanced functional connectivity and volume between cognitive and reward centers of naïve rodent brain produced by pro-dopaminergic agent KB220Z
por: Febo, Marcelo, et al.
Publicado: (2017)

Improving the Assessment of Neonatal Abstinence Syndrome (NAS)
por: Chin Foo, Claire A., et al.
Publicado: (2021)

Evidence for the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2023)

Neuroplasticity of the extended amygdala in opioid withdrawal and prolonged opioid abstinence
por: Kaplan, Gary B., et al.
Publicado: (2023)

Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hlgoeb8a339tikeanm5q3q9b9f